Navigation Links
BioMarin Announces Third Quarter 2009 Financial Results
Date:10/28/2009

.

Forward-Looking Statement

This press release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including, without limitation, statements about: the expectations of revenue and sales related to Naglazyme, Kuvan, and Aldurazyme; the financial performance of the BioMarin as a whole; the timing of BioMarin's clinical trials of PEG-PAL, GALNS and other product candidates; the continued clinical development and commercialization of Aldurazyme, Naglazyme, Kuvan, and its product candidates; and actions by regulatory authorities, particularly with respect to the recently acquired 3,4-DAP product. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others: our success in the continued commercialization of Naglazyme and Kuvan; Genzyme Corporation's success in continuing the commercialization of Aldurazyme; results and timing of current and planned preclinical studies and clinical trials; our ability to successfully manufacture our products and product candidates; the content and timing of decisions by the U.S. Food and Drug Administration, the European Commission and other regulatory authorities concerning each of the described products and product candidates; the market for each of these products and particularly Aldurazyme, Naglazyme and Kuvan; actual sales of Aldurazyme, Naglazyme and Kuvan; Merck Serono's activities related to Kuvan; and those factors detailed in BioMarin's filings with the Securities and Exchange Commission, including, without limitation, the factors contained under the caption "Risk Factors" in BioMarin's 2008 Annual Report on Form 10-K, and the factors contained in BioMarin's reports on Form 10-Q. Stockholders are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. BioMarin is u
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine technology :

1. BioMarin to Present at the Oppenheimer Healthcare Conference
2. BioMarin Acquires Huxley Pharmaceuticals, Inc.
3. BioMarin Initiates Phase 2 Clinical Study of PEG-PAL in PKU
4. BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome
5. BioMarin Announces Positive Results From Phase 2A Clinical Study of 6R-BH4 in Sickle Cell Disease
6. BioMarin Initiates Phase 1 Clinical Study of PEG-PAL in PKU
7. BioMarin Announces FDA Approval for Kuvan
8. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
9. Rigel Announces Presentations at Two Investor Conferences
10. Onyx Pharmaceuticals Announces Third Quarter 2009 Financial Results Teleconference and Webcast
11. STAAR Surgical Announces Third Quarter 2009 Earnings Release Date and Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... Genomic Health, Inc. (Nasdaq: GHDX ) ... Onco type DX® breast cancer test, a multi-gene ... likelihood of chemotherapy benefit and recurrence risk for patients ... the 32nd Annual CTRC-AACR San Antonio Breast Cancer Symposium, ... TX. ,, "The breadth of data presented at last ...
(Date:12/15/2009)... Arlington Medical Resources (AMR) and Decision ... (MRSA) is the most concerning pathogen to surveyed ... treatment of skin and skin structure infections. A ... factors that influences European physician drug selection for ... factors that drive prescribing include an agent,s skin ...
(Date:12/15/2009)... INDIANAPOLIS, and CAMBRIDGE, Mass., Dec. 15 ... ), Eli Lilly and Company (NYSE: ... ) today announced positive results from a head-to-head ... therapy, to BYETTA® (exenatide) injection taken twice daily, ... weeks of treatment, patients taking exenatide once weekly ...
Breaking Medicine Technology:Genomic Health Announces New Data Reinforcing Clinical Utility of Oncotype DX(R) in Multiple Breast Cancer Populations 2Genomic Health Announces New Data Reinforcing Clinical Utility of Oncotype DX(R) in Multiple Breast Cancer Populations 3Genomic Health Announces New Data Reinforcing Clinical Utility of Oncotype DX(R) in Multiple Breast Cancer Populations 4Genomic Health Announces New Data Reinforcing Clinical Utility of Oncotype DX(R) in Multiple Breast Cancer Populations 5Genomic Health Announces New Data Reinforcing Clinical Utility of Oncotype DX(R) in Multiple Breast Cancer Populations 6Genomic Health Announces New Data Reinforcing Clinical Utility of Oncotype DX(R) in Multiple Breast Cancer Populations 7A Drug's Activity Against MRSA is Among the Top Factors That Influences European Physician Antibiotic Selection for Treating Skin and Skin Structure Infections 2A Drug's Activity Against MRSA is Among the Top Factors That Influences European Physician Antibiotic Selection for Treating Skin and Skin Structure Infections 3Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study 2Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study 3Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study 4Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study 5Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study 6Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study 7Study Forecasts More Young Doctors in Future 59852 1Study Forecasts More Young Doctors in Future 59852 2Experimental treatments restore partial vision to blind people 10444 1Experimental treatments restore partial vision to blind people 10444 2Minnesota Dentists Warn Halloween Shoppers 3A Sour Candies May Trick Not Treat Teeth 59846 1Minnesota Dentists Warn Halloween Shoppers 3A Sour Candies May Trick Not Treat Teeth 59846 2
... Drugs on the Market and, in Clinical Development with Each ... Anticancer Effects, and Expand the Markets for ... ... Identification of novel,cancer-related targets and pathways is redefining our understanding of ...
... Mich., Feb. 19 Compendia Bioscience, Inc.,today announced ... renewed,and expanding commitment from all major customers and ... to its customer roster. The new,customers and existing ... revenue increase, with similar growth forecasted for 2008., ...
Other Medicine Technology:Oncology Drug Development Update - Molecular Profiling Redefines the Nature of Malignancy and Increases the Adoption of Targeted Therapeutics 2Oncology Drug Development Update - Molecular Profiling Redefines the Nature of Malignancy and Increases the Adoption of Targeted Therapeutics 3Oncology Drug Development Update - Molecular Profiling Redefines the Nature of Malignancy and Increases the Adoption of Targeted Therapeutics 4On Second Anniversary, Compendia Bioscience Announces Significant Revenue Growth, Completion of Product Milestone and Expansion of Pharma Customer Commitments 2On Second Anniversary, Compendia Bioscience Announces Significant Revenue Growth, Completion of Product Milestone and Expansion of Pharma Customer Commitments 3
(Date:12/15/2009)... LocumTenens.com named 4th Best Staffing Firm to Work For. , ... ... Analysts has named LocumTenens.com, a leading provider of temporary physician and ... on their inaugural 2009 list., , , , ,“We are proud ... we care about investing in our associates,” said R. Shane Jackson ...
(Date:12/15/2009)... your trust as the most caring, conscientious practice you have ever ... the Dermatology Center of Dallas, we can help to achieve this ... ... (PRWEB) December 15, 2009 -- The Dermatology Center of Dallas, a ... arrival of Jeri Beth “J.B.” Foshee, MD in their practice. ...
(Date:12/15/2009)... of Spa, Massage, and Medical tables announces its partnership with ... comfort system to ease pressure felt while laying face down ... ... Pennsylvania (PRWEB) December 15, 2009 -- OAKWORKS®, Inc., the premier ... the launch of the Utopian Massage Table with patent pending ...
(Date:12/15/2009)... ... 2009 -- Millions of men and women suffer from spider veins ... or purple veins that spider-web across the nose, cheeks, legs and ankles. ... that 25-30% of women and 10-20% of men suffer from this unsightly ... been available for over 8 years in Europe (where it is enjoyed ...
(Date:12/15/2009)... Dec. 15 "The entire San Diego Hospice ... passing of Sol Price on December 14, 2009. Mr. ... integrity, loyalty and ethics in his business, community and ... humanitarian who truly understood the responsibility of philanthropy and ... legacy will live on through his countless philanthropic efforts. ...
Breaking Medicine News(10 mins):Health News:LocumTenens.com Named 4th Best Staffing Firm to Work For 2Health News:Jeri Beth “J.B.” Foshee, MD Joins Dermatology Center of Dallas 2Health News:Wellness Equipment Manufacturer Announces Revolutionary New Adjustable Breast Comfort System Available on Utopian Portable Massage Table 2Health News:Wellness Equipment Manufacturer Announces Revolutionary New Adjustable Breast Comfort System Available on Utopian Portable Massage Table 3Health News:Wellness Equipment Manufacturer Announces Revolutionary New Adjustable Breast Comfort System Available on Utopian Portable Massage Table 4Health News:Vein Center & CosMed, Inc. Selected as Exclusive St. Louis Provider of FDA-Cleared Device 2Health News:San Diego Hospice and The Institute for Palliative Medicine on the Passing of Sol Price 2
... Men who have too much calcium in their bloodstreams ... according to a new analysis from Wake Forest University ... "We show that men in upper range of the ... three-fold increased risk for fatal prostate cancer," said Gary ...
... Foundation of Patient Driven Medicine, Note: September ... 2 Insurance,companies are denying Fibromyalgia patients proper ... are having a difficult time getting,their fibromyalgia patients ... the FDA fast tracked prescription medicine,Lyrica and now ...
... Fla., Sept. 2 MBF Healthcare,Acquisition Corp. ... special purpose,acquisition company, announced today the amendment ... acquisition of Critical Homecare Solutions,Holdings, Inc. ("CHS"), ... dated February 6, 2008 (the "Stock Purchase ...
... Cogdell Spencer Inc.,(NYSE: CSA ) announces the ... million medical office building and outpatient treatment center ... is the first synergy project since the,closing of ... Erdman, A,Cogdell Spencer Company). The project will include ...
... eat unhealthy foods, study suggests , , TUESDAY, Sept. ... who pick up the stress of their anxious mothers ... their risk of becoming overweight, a new study says. ... secure, meaning they have access to a sufficient amount ...
... Cole, Leona Lewis, Mariah, Carey, Mary J. Blige, Miley Cyrus, Rihanna, Natasha ... ... Sept 2 Conde Nast Media Group announced today,that Ashanti, Carrie Underwood, ... Rihanna, Natasha Bedingfield, and,Sheryl Crow will join together on stage at Radio ...
Other Medicine News:Health News:Too much calcium in blood may increase risk of fatal prostate cancer 2Health News:Too much calcium in blood may increase risk of fatal prostate cancer 3Health News:Important Information on Fibromyalgia and Access to Treatments 2Health News:Important Information on Fibromyalgia and Access to Treatments 3Health News:MBF Healthcare Acquisition Corp. Amends Stock Purchase Agreement With Critical Homecare Solutions Holdings, Inc. to Extend Termination Date to October 31, 2008 2Health News:MBF Healthcare Acquisition Corp. Amends Stock Purchase Agreement With Critical Homecare Solutions Holdings, Inc. to Extend Termination Date to October 31, 2008 3Health News:MBF Healthcare Acquisition Corp. Amends Stock Purchase Agreement With Critical Homecare Solutions Holdings, Inc. to Extend Termination Date to October 31, 2008 4Health News:Cogdell Spencer Announces First Synergy Project in Pensacola, Florida 2Health News:Cogdell Spencer Announces First Synergy Project in Pensacola, Florida 3Health News:Kids of Stressed, Low-Income Moms Prone to Weight Problems 2Health News:Kids of Stressed, Low-Income Moms Prone to Weight Problems 3Health News:Conde Nast Media Group Announces Performance of 'Just Stand Up' to be Fed Live from the Stage at FASHION ROCKS to ABC, CBS and NBC's Simultaneous Broadcast of Stand Up To Cancer Nationwide Fund-Raising Event On September 5th 2Health News:Conde Nast Media Group Announces Performance of 'Just Stand Up' to be Fed Live from the Stage at FASHION ROCKS to ABC, CBS and NBC's Simultaneous Broadcast of Stand Up To Cancer Nationwide Fund-Raising Event On September 5th 3
For the quantitative determination of uric acid in serum....
... new level of immunodiagnostic productivity. Optimal flexibility. ... laboratory automation system. No-pause loading of all ... only immunoassay system with this capability. No ... without any additional setup. Continuous sample loading. ...
... Engineered for continuous, random access operation, the ... medium to large volume laboratories that want ... offers the simplicity, flexibility and Stat capabilities ... can be adapted to the changing needs ...
The Dimension RxL Max is an integrated chemistry system and is the most powerful and technologically advanced Dimension analyze with new standard for excellence in clinical diagnostics. Simply put, t...
Medicine Products: